BACKGROUND: Despite the increasing use of ventricular assist devices (VADs), gender differences in indications, hemodynamics, and outcome are not well understood. We examined gender differences and gender-specific predictors for perioperative outcome in patients on ventricular support. METHODS: Multicenter data of 966 patients (median age 55 years, 151 women) from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) were analyzed. Median follow-up was 1.26 years. RESULTS: At the time of VAD implantation, women were more often in an unstable condition (Interagency Registry for Mechanically Assisted Circulatory Support [INTERMACS] profile 1 and 2) (51.7% vs 41.6% in men), experiencing significantly more often major bleeding (p ¼ 0.0012), arrhythmias (p ¼ 0.022), and right ventricular (RV) failure (p o 0.001) with need for additional RV support. The survival of women on isolated LVAD support was significantly worse (1-year survival 75.5% vs 83.2% in men). Age-adjusted Cox regression analyses showed significant associations with mortality for preoperative inotropic therapy, percutaneous mechanical support, INTERMACS profile 1 and 2, RV dysfunction, major bleeding, cerebral bleeding, ischemic stroke, and RV failure. In women, pump thrombosis was more strongly related with mortality compared to men, while the direction of the association of renal dysfunction with mortality was different for women and men (p-value interaction 0.028 and 0.023, respectively).
CONCLUSIONS: Women and men differ in perioperative hemodynamics, adverse events, and mortality after VAD implantation. A gender-dependent association of pump thrombosis with mortality was seen. The impact on treatment practice needs to be shown.
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Due to the growing organ shortage and technical progress, ventricular assist devices (VADs) are gaining importance in the treatment of end-stage heart failure (HF). Women and men differ in terms of HF etiology, diagnosis, prognosis, and treatment. 1 Women have a higher HF incidence than men. 2 Women are hospitalized more frequently and die more often than men from the consequences of HF. 3 Although women are hospitalized in more advanced states of decompensated HF, 4 VAD placement is far less likely. 5, 6 At time of implantation, women are more frequently in cardiogenic shock (Interagency Registry for Mechanically Assisted Circulatory Support [INTER-MACS] level 1) 7 and receive devices with smaller pump sizes. 8 After VAD implantation, women require longer ventilatory and inotropic support resulting in prolonged intensive care stays. 7 Furthermore, women have a higher risk for neurologic complications and perioperative right ventricular (RV) failure requiring additional RV support. 6, 7, 9 However, there is contradictory evidence regarding gender-specific outcome. [4] [5] [6] [7] Therefore, in the largest European study sample of patients undergoing mechanical circulatory support to date, the European Registry for Patients with Mechanical Circulatory Support (EURO-MACS), we aimed to further evaluate gender differences in adverse events. Additionally, we tried to identify gender-specific predictors for survival of women and men undergoing VAD implantation.
Methods

Study population
Between January 2011 and June 2014, 966 patients were prospectively enrolled into EUROMACS, an online database collecting anonymized data of demographics, device implantation, and long-term follow-up of patients with ventricular support. 10 At the present time, more than 50 European and non-European centers from 15 countries are involved. Preimplantation data regarding patient characteristics, social situation, HF medication at admission, preoperative blood values, primary cardiac diagnosis, and INTERMACS profile are recorded. Data on the following device strategies are available: bridge to recovery, bridge to transplantation (possibly bridged, currently listed), destination therapy, rescue therapy, and others. Hemodynamic data from echocardiography and right heart catheter, intraoperative characteristics, and procedural characteristics are stored. Adverse events, including ischemic strokes, cerebral bleeding, arrhythmias, pump thrombosis, major bleeding, major infections, RV failure, and renal and hepatic dysfunction are indicated. The definition of adverse events in EUROMACS corresponds to the INTERMACS definition.
10,11 Every follow-up visit and all adverse events, including death of a patient, are reported. All contributing centers were contacted to confirm correctness of data by the end of follow-up. Pediatric patients were excluded.
Statistical methods
After exclusion of pediatric patients and 1 patient with missing device information, the data set consisted of 966 patients undergoing long-term VAD support. Patients receiving right ventricular assist device (RVAD), biventricular assist device (BIVAD), total artificial heart, CircuLite Synergy, HeartWare MVAD, or not-specified device brands were excluded from all survival analyses (including survival and incidence estimation and Cox regression analyses).
Available-case analyses, also known as pairwise deletion, were used. For each computation, only cases without missing values on the variables involved in that particular analysis were used. For continuous variables, median (25th, 75th percentile) is given, and Mann-Whitney test is performed. For categorical variables, absolute and relative frequencies are given, and Fisher exact test is performed. Gender-specific survival curves on LVAD and temporary RVAD therapy were drawn using the Kaplan-Meier method. The equality of the survival curves was tested using the log-rank test. Cumulative incidence functions were computed for the outcomes transplantation, death, and recovery for each gender using a competing risks approach. Equality of these functions was tested by Gray's test. Incident gender-specific adverse event rates are given. We performed Cox regression analyses to examine the extent to which selected hemodynamic parameters (analyses shown for preoperative inotropic therapy, percutaneous mechanical circulatory support, INTERMACS profile 1 and 2, and RV function) and adverse events (analyses shown for major bleeding, cerebral bleeding, ischemic stroke, pump thrombosis, RV failure, and renal dysfunction) were associated with survival for each gender. All Cox models were adjusted for age, gender, and LVAD brand. Each adverse event was used as a time-dependent covariate in the respective Cox model. Besides the predictor of interest (hemodynamic parameter, adverse event), the models include age, device type, gender, and an interaction term for gender and the predictor of interest. Cox models that do not include the aforementioned interaction term were also computed. Confidence intervals (CI) and p-values for the variable of interest were computed using the methods described by Figueiras et al. 12 Analyses were performed using R version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/).
Results
Gender-specific preoperative characteristics
Selected baseline characteristics of the study sample are presented in Table 1 (for further baseline characteristics see Table S1a ; missing value information is provided in Table S1b , available in the online version of this article at www.jhltonline.org). Patients (n = 966) (median age 55 years, 151 [15.6%] women, 84% European origin) underwent primary ventricular support (LVAD, n ¼ 790; BIVAD, n ¼ 52; LVAD with temporary RVAD, n ¼ 99; isolated RVAD, n ¼ 10; total artificial heart, n ¼ 15). Ischemic cardiomyopathy was less frequent in women than in men, whereas prevalence of dilated cardiomyopathy was higher in women (Table 1) . At the time of VAD implantation, women were more often in unstable condition (INTERMACS profile 1 or 2), although preoperatively no differences were seen in need for renal replacement therapy, ventilation, or percutaneous mechanical circulatory support.
Gender-specific intraoperative and postoperative characteristics
More women had moderate or severe mitral and tricuspid regurgitation but less aortic regurgitation resulting in less concomitant aortic valve replacement (Tables 2 and 3 ; additional hemodynamic parameters and procedural characteristics are given in Tables S2 and S3 , available in the online version of this article at www.jhltonline.org). Choice of device brands differed between genders ( Table 3 ). The HeartWare HVAD was significantly more often implanted in women. Women needed more additional RV support. In women, longer postoperative ventilatory support and a trend towards a longer stay in the intensive care unit were reported. 
Gender differences in adverse events
Survival and predictors for mortality
Women receiving isolated left ventricular support showed a significantly worse overall survival ( Figure 2 ). Survival of women receiving LVAD with temporary RVAD support was even worse but did not differ significantly from men ( Figure 2 ). No gender differences in transplant rates were seen (Figure 3 ). Parameters mirroring hemodynamic compromise were shown to predict survival on VAD support. Preoperative inotropic therapy, percutaneous mechanical support, INTERMACS profile 1 and 2, and highly reduced RV function were related to mortality (Table S4 , available in the online version of this article at www. jhltonline.org) with a significant gender interaction for the association of percutaneous mechanical circulatory support and mortality (Table 4) . In a refining analysis, which included these variables in a single model, INTERMACS profile 1 and 2 and preoperatively highly reduced RV function were no longer associated with mortality in both genders (Table S5 , available in the online version of this article at www.jhltonline.org). Furthermore, several VAD-related adverse events were significantly related to mortality. After adjustment for age, gender, and device brand, major bleeding, cerebral bleeding, ischemic stroke, pump thrombosis, RV failure, and renal dysfunction were significantly associated with mortality in the overall cohort (Table S6 , available in the online version of this article at www.jhltonline.org). In a refining analysis with gender interaction (Table 5) , the associations persisted in women and men, with the exception of renal dysfunction in women. A significant gender interaction in the association of pump thrombosis with mortality was observed indicating a stronger association in women ( Table 5 ). The associations remained statistically significant after further adjustment for body mass index, diabetes, systolic blood pressure, chronic obstructive pulmonary disease, and symptomatic peripheral vascular and carotid artery disease (analyses not shown). 
Discussion
We demonstrated significant gender differences not only in the perioperative period but also in the long-term course after VAD implantation. Women were shown to receive less VAD support despite a more critical HF state at admission. Both genders differed for implanted device types with implantation of smaller device pumps in women. Women required temporary or permanent RV support more often due to a higher incidence of RV failure. Overall survival in women was significantly worse. In contrast to prior smaller studies with a comparatively low number of women, 4, 6 our sample represents the largest European registry and one of the largest cohorts worldwide that permits the investigation of gender differences in longterm mechanical support. Compared with the earlier report on gender differences by Hsich et al 13 in INTERMACS, our study is characterized by a longer follow-up time after VAD implantation and by a higher rate of continuous-flow devices (HeartMate II and HeartWare HVAD). The latter have almost completely replaced pulsatile systems. Thus, our study mirrors current daily clinical practice with a stateof-the-art technology.
Gender-specific periprocedural characteristics
Despite a higher probability of hemodynamic compromise, 4, 7 women still are less likely to receive assist device support. 4, 5 Women are underrepresented in large multicenter trials as stated by the American College of Cardiology/ American Heart Association 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult.
14 Accordingly, women comprised only 15.6% of our study population, which is slightly lower than in comparable international registries such as INTERMACS. Whether this is due to European referral strategies or preferred device types cannot be answered by our data. Women presented significantly more often in INTERMACS level 1 and 2. This may be explained by 2 reasons: First, women are more likely to be transferred for VAD implantation in a later and more critical clinical state. Second, the smaller intrathoracic volume of women is not suited for larger pump sizes. We and others have shown that the smaller HeartWare HVAD pump was preferred in women. 8 Despite the more unstable condition at admission of women, there were no differences in inotropic therapy or percutaneous mechanical support. Consistent with prior reports, 7 women needed longer 6 which is explained by the fact that women have coronary artery disease less often than men. 15 
Gender-specific adverse events
In line with the report by Boyle et al, 16 who showed that women have a higher risk for bleeding complications on continuous-flow assist devices, women had a higher rate of major bleeding after VAD implantation in our cohort.
The assumption that differences in blood coagulation or gender-specific pharmacokinetics and pharmacodynamics of anticoagulant medication are driving the bleeding risk is pathophysiologically plausible, but this cannot be answered by our current data. In addition, women and men differed in RV hemodynamics. In line with prior studies, 6, 7 we showed that women had a higher incidence of perioperative RV failure requiring more additional RV support, although no difference in preoperative RV function was seen. With respect to the observed higher incidence of arrhythmias in women, RV failure may partly be explained by the occurrence of arrhythmias. In particular, ventricular arrhythmias have the potential to induce RV failure under LVAD support. Figure 1 Gender-specific adverse event rates. Events per patient year are given for women (red; n ¼ 136) and men (blue; n ¼ 739). Patients with RVAD, BIVAD, total artificial heart, CircuLite Synergy, HeartWare MVAD, and not-specified device brands were excluded from analysis.
A possible relationship of device type and specific adverse events has to be considered. The HeartWare HVAD, which was significantly more often implanted in women, has been related to a higher rate of cerebrovascular events. 18 The centrifugal flow of the HeartWare HVAD pump was associated with a hypercoagulable state, 19 which renders thromboembolic events more plausible. Prior investigations showed that anticoagulation, antiplatelet therapy, and blood pressure management affected stroke rate after HeartWare HVAD implantation. 20 In our study, after adjustment for LVAD brands, the association of cerebral bleeding, ischemic stroke, and pump thrombosis with mortality did not change markedly. Therefore, the association of these adverse events with mortality cannot be explained by the device choice.
Survival and predictors for mortality
There is conflicting evidence for survival differences between genders undergoing VAD therapy across heterogeneous studies with mostly smaller numbers of participants and different device types. In studies performed with several device types, continuous-flow systems were shown to be related to better survival rates. 21 Morgan et al 4 found a significantly worse survival for women undergoing pulsatile-flow support. In contrast to other studies, which did not see differences in short-term survival, 6, 7, 9, 13 women had a significantly worse 1-to 3-year survival in our study population. Our data provide evidence for 3 possible reasons for our findings. First, women were shown to present to the hospital in more advanced HF states. 4 Second, women suffered significantly more often from perioperative RV failure. Third, women are more likely to experience arrhythmias and major bleeding complications. In line with Shah et al, 22 we showed that need for percutaneous mechanical support was associated with perioperative mortality in both, women and men. INTERMACS profiles 1 and 2, which represent a clinically unstable condition, were identified to predict survival. We directly linked RV hemodynamics with mortality in both genders. In women with need for LVAD and temporary RVAD support, the probability of death was 38% at 1 year compared with 25% for women undergoing isolated LVAD support. This means that once temporary RVAD support is needed, the survival is significantly worse. However, as soon as women undergo additional RV support, no differences in outcome are seen compared to men with biventricular support. Whether a better preoperative evaluation of the right ventricle and a stricter determination of indication would improve the outcome on mechanical circulatory support needs to be further investigated.
In addition, the significant association of pump thrombosis with mortality was stronger in women. Prior studies showed that women experience thromboembolic events more often under VAD support and therefore may need more intensive anticoagulation. 9, 23 Prospective studies are needed to verify if gender-specific anticoagulation regimens would reduce thromboembolic complications and improve survival of women on long-term assist device support.
Limitations
Data quality of a large registry relies on the data input of the participating centers. Therefore, the possibility exists that not all adverse events were reported. Furthermore, the very nature of a registry allows no analyses on center-specific trends and device choices.
Conclusions
In conclusion, we were able to demonstrate in a large European sample that women and men undergoing VAD support differ in preoperative condition, perioperative hemodynamics, adverse events, and survival. Women were shown to have a higher incidence of major bleeding, arrhythmias, and perioperative RV failure and a worse early and long-term survival. Several hemodynamic parameters and adverse events predicted survival in both, women and men. The association of pump thrombosis with mortality was stronger in women. Whether changes in referral strategies, implant timing, and gender-specific outpatient aftercare may improve outcome for women on VAD support needs to be investigated.
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Figure 2
Kaplan-Meier survival curves by gender and assist types (with mortality as endpoint). Patients who died or were censored in the first 30 days after surgery were excluded from analysis. Follow-up was censored at transplantation or recovery. Results of log-rank test (men vs women): LVAD, p ¼ 0.046; LVAD, temporary RVAD, p ¼ 0.50. Numbers at risk are given below the Kaplan-Meier curves. Patients with RVAD, BIVAD, total artificial heart, CircuLite Synergy, HeartWare MVAD, and not-specified device brands were excluded from analysis. Cumulative incidence functions for both, women and men with the outcomes transplantation, death, and recovery. The probability of being alive without transplantation or recovery is also shown. Results of Gray's-Test (men vs. women): transplanted: p = 0.33; dead: p = 0.004; recovered: p = 0.81. Numbers at risk are shown below the curves. Patients with RVAD, BIVAD, total artificial heart, CircuLite Synergy, HeartWare MVAD, and not-specified device brands were excluded from analysis. All models are adjusted for age and LVAD brand. Patients receiving RVAD, BIVAD, total artificial heart, CircuLite Synergy, HeartWare MVAD, or notspecified device brands were excluded. Numbers vary slightly due to missing value information. CI, confidence interval; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; RV, right ventricular. a statistically significant.
b Hazard ratios for mildly and moderately reduced RV function are not shown.
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